PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago
"Finding a needle in a haystack - 4 molecules out of a million"
NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/
-- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on
developing proprietary targeted medicines for cancer treatment and Debiopharm
Group (Debiopharm), a group of companies with a focus on the developme...
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive
worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This te...
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced entry into an exclusive
license and collaboration agreement to commercialize Intermezzo ((R)) (z...
Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software
Terrosa Technologies, a provider of Cloud and SaaS migration services and SaaS based applications, announces it has exclusive
world wide sales, marketing and distribution responsibilities with Integrated Clinical Solutions for its Inclinicalperform application. Inclinicalperform is software-as-a-...
Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
PORTLAND, Ore., July 22 /PRNewswire/ -- Global One Principal Irl M. Davis today announced a relationship with Saigene Biotech, Inc. for the introduction and sale of a new class of harmful algae bloom detection technology in ASEAN nations, China, and Bangladesh. Global One, a consul...
Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
Hygeia Therapeutics has added to its portfolio of topical hormonal modulators with the acquisition of a series of potent topical anti-androgens. The compounds are expected to be devoid of systemic activity and will be developed for skin and hair disorders associated with increased sensitivity to...
PDI and The Medical Affairs Company Enter Exclusive Strategic Alliance
SADDLE RIVER, N.J. and KENNESAW, Ga., June 3 /PRNewswire-FirstCall/ -- Two leaders in the pharmaceutical contract services industry, PDI, Inc. (Nasdaq: PDII ), a provider of sales and marketing support to U.S. pharmaceutical companies, and The Medical Affairs Company (TMAC(R)), the leading provi...
Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
NEWTON, Mass., June 3 /PRNewswire-FirstCall/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and POWREX Corporation have entered into an exclusive
distributorship agreement whereby POWREX will market, sell and service Microfluidize...
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Cytokinetics Receives Exercise Fee of $50 Million
Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET
SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK ) and Amgen Inc. (Nasdaq: AMGN ) ...
Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital
LA JOLLA, Calif., May 15 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive
intellectual property rights jointly owned by Children's Hospital Boston and Massachusetts General Hospital. This intellectual property covers compositions and methods for supportin...
NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
License Strengthens NeoStem's Portfolio of Regenerative Treatments
NEW YORK, May 11, /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it ha...
NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
NEW YORK, May 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an agreement to license the exclusive
worldwide rights to an inno...
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu
ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc. , (Nasdaq: CLRT ), a premier anatomic pathology and mol...
Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
ST. LOUIS and MOUNTAIN VIEW, Calif., March 31 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL ) today announced an agreement to supply high quality services and oligonucleotides to Gene Oracle, an innovative gene synthesis company. Under the terms of the agreement, Sigma-Aldrich will be...
Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN), told the editors of The Wall Street Transcript, a New York City financial news weekly, that there is an excellent possibility that the company ...
Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
ANTONY, France, March 24 /PRNewswire-FirstCall/ -- Stallergenes S.A. and
Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary of Solvay
Group) announce the signing of an exclusive
partnership agreement for the
promotion and distribution of Stallergenes diagnostic and treatment product...
Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio
NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive
worldwide rights to a small mo...
Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
TORONTO, March 9 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that it has signed a license agreement with Toray Industries, Inc. of Japan granting Spectral the exclusive
development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic device for the t...
China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets
HARBIN, China, Feb. 24 /PRNewswire-Asia-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), today announced that its...
NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
License enhances NeoStem's Presence in Anti-Aging Arena
NEW YORK, Feb. 23 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has sign...
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C
TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...
S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
SINGAPORE and SAN DIEGO, Jan. 21 /PRNewswire/ -- S*BIO Pte Ltd and Tragara Pharmaceuticals Inc. today announced that S*BIO has granted a worldwide exclusive
license to Tragara to develop and commercialize its novel multi-kinase inhibitor SB1317.
Under the terms of the agreement S*BIO is elig...
Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry
NEW YORK, Jan. 14 /PRNewswire/ -- With all the woes of the U.S. economy, many people and businesses are looking to China for better opportunities. After all, China is expected to become the fifth-largest pharmaceutical market in the world by 2010. As the world watches, China is becoming a drivin...
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
REHOVOT, Israel and JERSEY CITY, New Jersey, January 8
/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading
developer of microRNA-based molecular diagnostics, announced today it has
signed an exclusive
distribution agreement with Teva Pharmaceutical
Industries Ltd. Under...
Nikon Instruments Introduces Exclusive VAAS Detector Imaging Method for Confocal Microscopy
Unique Technology Greatly Improves Signal to Noise
MELVILLE, N.Y., Dec. 15 /PRNewswire/ -- Nikon Instruments, Inc. ( www.nikoninstruments.com ) today launched VAAS Detection, a new, exclusive
confocal imaging method for post acquisition recovery of data normally lost during the course of...
Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts
HAMBURG, Germany, December 11 /PRNewswire/ -- Olympus has further
cemented its position as a leader in the field of minimally invasive surgery
by signing an exclusive
and immediate deal to distribute the products of
Irish company Advanced Surgical Concepts worldwide. ASC is the sole global
FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
ALEXANDRIA, Va., Dec. 9 /PRNewswire-USNewswire/ -- First Coast Service Options (FCSO) has selected Burgess, recognized as an industry leader in Medicare reimbursement solutions, to support a new Medicare contract awarded recently by the Centers for Medicare & Medicaid Services (CMS).
Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics
OMAHA, Neb. and HOUSTON, Dec. 2 /PRNewswire-FirstCall/ -- Transgenomic,
Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC
Bulletin Board: PWRM) today announced that Transgenomic has signed a letter of
intent to acquire exclusive
rights for Power3 Medical's Neurodegenerative
VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
International Agreement Licenses Seno's Opto-Acoustic Imaging Technology
To VisualSonics to Enable Molecular Imaging at the Cellular Level and Aid
in the Pursuit of Neurology, Regenerative Medicine, Inflammation, and
TORONTO and SAN ANTONIO, TX, Nov. ...
GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines
VIENNA, Austria, October 23 /PRNewswire/ -- GlaxoSmithKline Biologicals
S.A. (GSK) and AFFiRiS GmbH announced today the execution of a
collaboration agreement granting GSK exclusive
rights to AFFiRiS's
Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by
Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinba's Total Profit
XI'AN, China, Oct. 7 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-
Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB; the "Company"),
a leading developer and producer of plant extracts and pharmaceutical raw
materials for use in pharmaceutical, nutraceutical and food production in
The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
The HeartAssist 5™ Pediatric VAD will be introduced for the first time in the U.S. at the 16th annual meeting of the International Society for Rotary Blood Pumps (ISRBP) in Houston on Oct. 2-4.
HOUSTON (Business Wire EON) September 30, 2008 -- The Modern DeBakey...
Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq:
SIAL) announced today that it has entered into an exclusive
IsoSciences, LLC, to distribute isotopically labeled bioactive compounds
and their metabolites ( http://www.sigma-aldrich.com/isotope ) through its
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM ) announced today that it has entered into an exclusive
agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global
pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...
ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a
leader in human embryonic stem cell derived products, announced today that
it has entered into an exclusive
worldwide technology licensing agreement
with the University of Georgia Research Foundation that will enable the
PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology
AVON LAKE, Ohio, Aug. 5 /PRNewswire-FirstCall/ -- PolyOne Corporation
(NYSE: POL ), a premier provider of specialized polymer materials, services
and solutions, announced today that it has entered into an exclusive
license arrangement for a series of bio-based plasticizer technology
[video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.net's 3-Minute Press Show
WATERLOO, Ontario, July 31 /PRNewswire-FirstCall/ -- TurboSonic
Technologies, Inc. (OTC Bulletin Board: TSTA), a global leader in the
design and supply of industrial air pollution control technologies, today
announced that the company's CEO, Edward Spink is featured in an exclusive
Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15
/PRNewswire-FirstCall/ -- Agendia BV and Ferrer inCode today announced an
agreement that will give Ferrer exclusive
rights to sell two of Agendia's
signature cancer diagnostic services -- MammaPrint(R), a prognostic test
that uses a 70-g...
AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
AMSTERDAM, The Netherlands, July 15 /PRNewswire-FirstCall/ -- Amsterdam
Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene
therapy, today announced the start of a collaboration with St. Jude
Children's Research Hospital in Memphis, Tennessee, USA, on the development